Target intelligence / Profile preview

Gastrointestinal microbiota modulation

Molecular classification
Other
01

Overview

Gastrointestinal microbiota modulation" refers to deliberate and strategic interventions aimed at altering the composition and/or function of microbial communities within the gastrointestinal tract. These interventions include dietary approaches (prebiotics, probiotics, synbiotics), antibiotics, and fecal microbiota transplantation, each with distinct mechanisms to restore or maintain a healthy gut microbiome. Modulating the gut microbiota can influence immune responses, nutrient metabolism, epithelial barrier function, and inflammation, impacting a wide range of diseases such as cancer, infection, inflammatory and metabolic disorders. "Gastrointestinal microbiota modulation" itself is not a specific molecular target, receptor, enzyme, or protein, but a therapeutic strategy targeting the community structure and activity of the gut microbiota as an ecosystem, not an individual molecular entity[1][2][3][4][5].

Other names
Gut microbiota modulationModulation of gut microbiotaGut microbiome modulation
02

Mechanism of action

- Alteration of microbial composition to restore balance (eubiosis) - Enhancement of beneficial microbe activity - Suppression of pathogenic bacteria - Modulation of immune system signaling - Improvement of gut barrier integrity - Production of beneficial metabolites (e.g., short-chain fatty acids)

03

Biological functions

Regulation of immune responseMetabolism of nutrientsMaintenance of gut barrier functionModulation of inflammationInfluence on epigenetic regulation
04

Disease associations

CancerInflammationInfectious diseaseAllergic disordersNeurodegenerative diseaseCardiovascular diseaseGastrointestinal diseases (e.g., irritable bowel syndrome, inflammatory bowel disease, Clostridioides difficile infection)
05

Safety considerations

Risk of transferring multidrug-resistant organisms (especially with FMT)Potential for adverse immune reactionsIndividual variability in response to interventionsDisruption of gut microbial balance (dysbiosis)
06

Interacting drugs

Probiotics (such as Lactobacillus spp., Bifidobacterium spp.)

4 more in the full profile.

07

Biomarkers

Microbiota composition profiling (16S rRNA sequencing)Short-chain fatty acid levels (e.g., butyrate, acetate)Markers of intestinal inflammation (e.g., calprotectin)

Beyond the preview

Go deeper on Gastrointestinal microbiota modulation.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Gastrointestinal microbiota modulation.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call